Skip to main navigation Skip to search Skip to main content

Circulating resistin levels and risk of multiple myeloma in three prospective cohorts

  • Loredana Santo
  • , Lauren R. Teras
  • , Graham G. Giles
  • , Stephanie J. Weinstein
  • , Demetrius Albanes
  • , Ye Wang
  • , Ruth M. Pfeiffer
  • , Qing Lan
  • , Nathaniel Rothman
  • , Brenda M. Birmann
  • , Graham A. Colditz
  • , Michael N. Pollak
  • , Mark P. Purdue
  • , Jonathan N. Hofmann

Research output: Contribution to journalArticlepeer-review

Abstract

Background:Resistin is a polypeptide hormone secreted by adipose tissue. A prior hospital-based case-control study reported serum resistin levels to be inversely associated with risk of multiple myeloma (MM). To date, this association has not been investigated prospectively.Methods:We measured resistin concentrations for pre-diagnosis peripheral blood samples from 178 MM cases and 358 individually matched controls from three cohorts participating in the MM cohort consortium.Results:In overall analyses, higher resistin levels were weakly associated with reduced MM risk. For men, we observed a statistically significant inverse association between resistin levels and MM (odds ratio, 0.44; 95% confidence interval (CI) 0.24-0.83 and 0.54; 95% CI 0.29-0.99, for the third and fourth quartiles, respectively, vs the lowest quartile; P trend =0.03). No association was observed for women.Conclusions:This study provides the first prospective evidence that low circulating resistin levels may be associated with an increased risk of MM, particularly for men.

Original languageEnglish
Pages (from-to)1241-1245
Number of pages5
JournalBritish Journal of Cancer
Volume117
Issue number8
DOIs
StatePublished - Oct 10 2017

Fingerprint

Dive into the research topics of 'Circulating resistin levels and risk of multiple myeloma in three prospective cohorts'. Together they form a unique fingerprint.

Cite this